Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia

British Journal of Haematology

Volumn 157, Issue 1, 2012, Pages 131-132

  Mohan, Babu P ^a   How, Gee Fung ^a   Loh, Yvonne ^a   Linn, Yeh Ching ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Acute myeloid leukaemia; Fms related tyrosine kinase 3 internal tandem duplication; Sorafenib monotherapy

Indexed keywords

AZACITIDINE; CD135 ANTIGEN; SORAFENIB; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DYSPLASIA; FEMALE; FLT3 GENE; GENE; GENE REPRESSION; HUMAN; LETTER; MALE; MOLECULAR CLONING; MOLECULAR GENETICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84858293612     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08910.x     Document Type: Letter

References (10)

1. Levis, M., Pham, R., Smith, B.D. & Small, D. (2004) In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood, 104, 1145-1150.
2. Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., Baccarani, M., Cripe, L.D., Tallman, M.S., Meloni, G., Godley, L.A., Langston, A.A., Amadori, S., Lewis, I.D., Nagler, A., Stone, R., Yee, K., Advani, A., Douer, D., Wiktor-Jedrzejczak, W., Juliusson, G., Litzow, M.R., Petersdorf, S., Sanz, M., Kantarjian, H.M., Sato, T., Tremmel, L., Sen-Kennedy, D.M., Small, D. & Smith, B.D. (2011) Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 117, 3294-3301.
3. Metzelder, S., Wang, Y., Wollmer, E., Wanzel, M., Teichler, S., Chaturvedi, A., Eilers, M., Enghofer, E., Neubauer, A. & Burchert, A. (2009a) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood, 113, 6567-6571.
4. Metzelder, S., Scholl, S., Matthias, K., Reiter, A., Meyer, R.G., Heinicke, T., Giagounidis, A., Wolfgang, B., Vohringer, M., Stadler, M., Schultheis, B., Muller, L., Hanel, M., Hochhaus, A., Enghofer, E., Neubauer, A. & Burchert, A. (2009b) Compassionate use of sorafenib in relapsed and refractory Flt3-ITD positive acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts), 114, 2060.
5. Pratz, K. & Levis, M. (2008) Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leukaemia & Lymphoma, 49, 852-863.
6. Ravandi, F., Cortes, J.E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M.Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S.R., Brandt, M., Byrd, A., Bekele, B.N., Pratz, K., Luthra, R., Levis, M., Andreeff, M. & Kantarjian, H.M. (2010) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology, 28, 1856-1862.
7. Sato, T., Yang, X., Knapper, S., White, P., Smith, B.D., Galkin, S., Small, D., Burnett, A. & Levis, M. (2011) FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood, 117, 3286-3293.
8. Scholl, S., Spies-Weisshart, B., Klink, A., Muegge, L.O., Fricke, H.J. & Hochhaus, A. (2011) Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Annals of Hematology, 90, 473-475.
9. Schroeder, T., Saure, C., Bruns, I., Zohren, F., Czibere, A.G., Safaian, N.N., Fenk, R., Haas, R. & Kobbe, G. (2009) Clinical efficacy of sorafenib in patients with acute myeloid leukemia (AML) and activating FLT3-mutations. Blood (ASH Annual Meeting Abstracts), 114, 2057.
10. Serve, H., Wagner, R., Sauerland, C., Brunnberg, U., Krug, U., Schaich, M., Ottmann, O.G., Duyster, J., Wandt, H., Herr, W., Giagounidis, A.A.N., Neubauer, A., Reichle, A., Aulitzky, W.E., Noppeney, R., Blau, I.W., Kunzmann, V., Schmitz, N., Kreuzer, K.A., Kramer, A., Brandts, C., Steffen, B., Heinecke, A., Thiede, C., Muller-Tidow, C., Ehninger, G. & Berdel, W.E. (2010) Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial. Blood (ASH Annual Meeting Abstracts), 116, 333.